JMP Securities reiterated their buy rating on shares of Wave Life Sciences Pte. Ltd. (NASDAQ:WVE) in a report released on Thursday morning.

Several other research firms have also weighed in on WVE. Jefferies Group set a $28.00 price objective on Wave Life Sciences Pte. and gave the company a buy rating in a research note on Monday, August 15th. Leerink Swann reissued an outperform rating and set a $45.00 price target on shares of Wave Life Sciences Pte. in a research report on Thursday, November 10th. Finally, Zacks Investment Research raised Wave Life Sciences Pte. from a sell rating to a hold rating in a research report on Wednesday, October 19th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $33.60.

Shares of Wave Life Sciences Pte. (NASDAQ:WVE) opened at 37.35 on Thursday. The stock has a 50 day moving average price of $31.83 and a 200 day moving average price of $23.23. Wave Life Sciences Pte. has a 12-month low of $8.95 and a 12-month high of $38.50. The firm’s market capitalization is $875.48 million.

Wave Life Sciences Pte. (NASDAQ:WVE) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.14. Equities analysts anticipate that Wave Life Sciences Pte. will post ($2.17) earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Strs Ohio acquired a new stake in Wave Life Sciences Pte. during the third quarter valued at about $194,000. Deschutes Portfolio Strategy LLC acquired a new stake in Wave Life Sciences Pte. during the third quarter valued at about $334,000. Schwab Charles Investment Management Inc. acquired a new stake in Wave Life Sciences Pte. during the second quarter valued at about $428,000. State Street Corp acquired a new stake in Wave Life Sciences Pte. during the second quarter valued at about $1,752,000. Finally, Vident Investment Advisory LLC acquired a new stake in Wave Life Sciences Pte. during the second quarter valued at about $669,000. Institutional investors own 61.15% of the company’s stock.

Wave Life Sciences Pte. Company Profile

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

5 Day Chart for NASDAQ:WVE

Receive News & Stock Ratings for Wave Life Sciences Pte. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences Pte. Ltd. and related stocks with our FREE daily email newsletter.